Jiayi Li Xin Zhang Zhuanzhuan Mu Di Sun Yuqing Sun Yansong Lin
10.3389/fimmu.2022.943916
Front Immunol
2022 Aug 8;13:943916.
apatinib plus camrelizumab treatment combination immunotherapy differentiated thyroid cancer multitargeted kinase inhibitors plus pd-1/pd-l1 inhibitors therapy radioactive iodine refractory
CC BY
https://pubmed.ncbi.nlm.nih.gov/36003403/
Adenocarcinoma / drug therapy Thyroid Neoplasms / drug therapy Thyroid Neoplasms / pathology
Adenocarcinoma / drug therapy Thyroid Neoplasms / drug therapy Thyroid Neoplasms / pathology Case Reports Review Research Support, Non-U.S. Gov't Adult Antibodies, Monoclonal, Humanized Humans Immunotherapy Iodine Radioisotopes / therapeutic use Male Pyridines Antibodies, Monoclonal, Humanized Iodine Radioisotopes Pyridines apatinib camrelizumab
PMC9393697
36003403
Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review
2022